Abiopharma

🔍 Sheena Jonathan (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 258 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 262,452.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 127 shares of Common Stock at $204.1327 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 262,325.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: H | nature_of_ownership: By Caraluna 1 Trust | shares_owned_after: 21,782.00 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: H | nature_of_ownership: By Caraluna 2 Trust | shares_owned_after: 21,782.00 | Footnotes: F4

Footnotes:

• F1: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026.
• F4: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.